BioSpace News Archive

The Owens & Minor Foundation shared its achievements over the past year in delivering on its efforts to help build healthier communities.

Elicio Therapeutics, Inc. announced promising preliminary relapse-free survival data from the ongoing Phase 1 study of its lead asset, ELI-002.

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, announced the results from its annual meeting of shareholders.

SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the BREXAFEMME® tablets.

BrainStorm Cell Therapeutics Inc. announced the outcome of the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting to review the Biologics License Application for NurOwn®, an investigational mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis.

Immunovant, Inc. announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions.

Novel Biotechnology Inc. is pleased to announce the successful completion of its $2.5 million seed round funding.

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the acceptance of two abstracts (related to TAC-001 and TAC-003) at the SITC 38th Annual Meeting in San Diego, CA, from November 3-5, 2023.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2023 on Tuesday, October 3, 2023.

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Alport syndrome with setanaxib.